dupilumab
pivotal
data
showing
significant
improvement
eosinophilic
esophagitis
signs
symptoms
presented
first
time
scientific
meetings
dupilumab
pivotal
data
showing
significant
improvement
eosinophilic
esophagitis
signs
symptoms
presented
first
time
scientific
meetings
first
phase
trial
eosinophilic
esophagitis
eoe
show
biologic
medicine
significantly
improved
structural
histologic
measures
rapidly
improving
ability
swallow
patients
years
older
new
data
show
additional
improvements
disease
severity
extent
well
normalized
gene
expression
associated
type
inflammation
data
trial
supports
safety
profile
dupixent
results
presented
first
time
virtual
acg
ueg
week
dupixent
received
fda
breakthrough
therapy
designation
patients
years
older
eoe
paris
tarrytown
october
additional
positive
results
announced
part
pivotal
phase
trial
evaluating
investigational
use
dupilumab
patients
years
older
eosinophilic
esophagitis
eoe
previously
reported
trial
met
key
secondary
endpoints
new
data
showing
additional
improvements
disease
severity
extent
microscopic
level
well
normalization
gene
expression
pattern
associated
type
inflammation
presented
virtual
american
college
gastroenterology
acg
annual
scientific
meeting
united
european
gastroenterology
ueg
week
virtual
currently
medicines
eoe
chronic
progressive
inflammatory
disease
damages
esophagus
prevents
working
properly
time
excessive
type
inflammation
may
cause
scarring
narrowing
esophagus
making
difficult
swallow
eoe
affect
patient
ability
eat
cause
food
become
stuck
swallowed
food
impaction
lead
medical
emergency
previously
announced
results
showed
dupixent
improved
symptomatic
structural
histologic
measures
eoe
use
dupixent
treat
eoe
investigational
fully
evaluated
regulatory
authority
results
trial
show
dupilumab
significantly
improved
patients
ability
swallow
well
structural
abnormalities
esophagus
targeting
type
inflammation
help
reverse
tissue
damage
scarring
usually
worsens
time
said
evan
dellon
professor
gastroenterology
hepatology
university
north
carolina
school
medicine
principal
investigator
trial
results
also
demonstrate
eosinophilic
esophagitis
disease
caused
factors
beyond
presence
elevated
eosinophils
dupilumab
targets
activity
cytokines
drive
type
inflammation
able
show
significant
improvements
broad
range
clinical
anatomic
cellular
molecular
part
randomized
trial
enrolled
patients
aged
years
older
eoe
treated
dupixent
mg
weekly
treatment
period
placebo
new
results
presented
virtual
acg
ueg
week
showed
patients
treated
dupixent
experienced
rapid
improvement
ability
comfort
swallowing
patients
reported
significant
improvement
dysphagia
symptom
questionnaire
dsq
early
weeks
continued
improve
weeks
p
p
respectively
reduced
esophageal
eosinophil
count
diagnostic
disease
threshold
patients
treated
dupixent
achieved
eosinophils
field
eos
hpf
compared
placebo
weeks
p
peak
esophageal
eosinophil
count
reduced
dupixent
compared
placebo
baseline
p
reduced
severity
extent
disease
microscopic
level
grade
stage
scores
measure
esophageal
tissue
changes
associated
disease
reduced
dupixent
compared
reduction
placebo
weeks
eoe
histology
scoring
system
grade
stage
scores
measure
changes
eight
cellular
tissue
features
scales
respectively
p
values
normalized
gene
expression
esophageal
tissue
gene
expression
patterns
associated
type
inflammation
eoe
reduced
compared
reduction
placebo
respectively
measured
normalized
enrichment
score
nes
weeks
baseline
nes
evaluated
panel
genes
associated
type
inflammation
eoe
p
values
changes
observed
dupixent
demonstrate
shift
gene
expression
pattern
one
resembles
eoe
disease
pattern
resembles
healthy
controls
trial
demonstrated
similar
safety
results
safety
profile
dupixent
approved
indications
treatment
period
overall
rates
adverse
events
dupixent
placebo
adverse
events
commonly
observed
dupixent
included
injection
site
reactions
dupixent
placebo
upper
respiratory
tract
infections
dupixent
placebo
one
treatment
discontinuation
dupixent
group
due
joint
pain
september
fda
granted
breakthrough
therapy
designation
dupixent
treatment
patients
years
older
eoe
breakthrough
therapy
designation
designed
expedite
development
review
drugs
target
serious
conditions
drugs
qualifying
designation
must
show
preliminary
clinical
evidence
may
demonstrate
substantial
improvement
clinically
significant
endpoints
available
therapies
placebo
available
therapies
dupixent
also
granted
orphan
drug
designation
potential
treatment
eoe
given
investigational
medicines
intended
treatment
rare
diseases
affect
fewer
people
adequate
medicines
developed
approved
dupixent
monoclonal
antibody
inhibits
signaling
proteins
data
dupixent
clinical
trials
shown
key
drivers
type
inflammation
plays
major
role
atopic
dermatitis
asthma
chronic
rhinosinusitis
nasal
polyposis
crswnp
eosinophilic
esophagitis
dupixent
eosinophilic
esophagitis
trial
phase
randomized
trial
evaluated
efficacy
safety
dupixent
adolescents
adults
eosinophilic
esophagitis
part
trial
enrolled
patients
treated
dupixent
placebo
aged
years
older
eoe
determined
histological
measures
endpoints
assessed
change
baseline
dsq
measure
difficulty
swallowing
proportion
patients
achieving
peak
esophageal
intraepithelial
eosinophil
count
eos
hpf
measure
esophageal
inflammation
weeks
key
secondary
endpoints
trial
assessed
histopathologic
measures
severity
extent
tissue
scarring
esophagus
measured
grade
stage
scores
proportion
patients
achieving
peak
esophageal
intraepithelial
eosinophil
count
eos
hpf
weeks
secondary
endpoints
trial
assessed
nes
relative
change
baseline
week
eoe
diagnostic
panel
type
inflammation
transcriptome
signatures
total
patients
suffered
least
one
concurrent
atopic
condition
allergic
rhinitis
food
allergy
asthma
patients
received
weekly
subcutaneous
injections
dupixent
mg
placebo
treatment
period
eoe
trial
ongoing
additional
patients
enrolling
part
b
well
patients
continuing
extended
active
treatment
period
part
c
completing
either
part
part
b
part
b
trial
evaluating
additional
dupixent
dosing
regimen
dupixent
dupixent
approved
adolescents
adults
atopic
dermatitis
asthma
adults
crswnp
number
countries
around
world
including
european
union
japan
well
dupixent
also
approved
children
atopic
dermatitis
dupixent
currently
approved
countries
patients
treated
globally
dupilumab
development
program
date
dupilumab
studied
patients
across
clinical
trials
various
chronic
diseases
driven
type
inflammation
addition
currently
approved
indications
sanofi
regeneron
studying
dupilumab
broad
range
diseases
driven
type
inflammation
allergic
processes
including
eoe
phase
pediatric
atopic
dermatitis
months
years
age
phase
pediatric
asthma
years
age
phase
chronic
obstructive
pulmonary
disease
phase
bullous
pemphigoid
phase
prurigo
nodularis
phase
chronic
spontaneous
urticaria
phase
food
environmental
allergies
phase
potential
uses
investigational
safety
efficacy
dupilumab
conditions
fully
evaluated
regulatory
authority
dupilumab
jointly
developed
sanofi
regeneron
global
collaboration
agreement
regeneron
regeneron
nasdaq
regn
leading
biotechnology
company
invents
medicines
people
serious
diseases
founded
led
years
unique
ability
repeatedly
consistently
translate
science
medicine
led
eight
treatments
numerous
product
candidates
development
homegrown
laboratories
medicines
pipeline
designed
help
patients
eye
diseases
allergic
inflammatory
diseases
cancer
cardiovascular
metabolic
diseases
pain
infectious
diseases
rare
diseases
regeneron
accelerating
improving
traditional
drug
development
process
proprietary
technologies
uses
unique
mice
produce
optimized
antibodies
bispecific
antibodies
ambitious
research
initiatives
regeneron
genetics
center
conducting
one
largest
genetics
sequencing
efforts
world
additional
information
company
please
visit
follow
regeneron
twitter
sanofi
sanofi
dedicated
supporting
people
health
challenges
global
biopharmaceutical
company
focused
human
health
prevent
illness
vaccines
provide
innovative
treatments
fight
pain
ease
suffering
stand
suffer
rare
diseases
millions
chronic
conditions
people
countries
sanofi
transforming
scientific
innovation
healthcare
solutions
around
globe
sanofi
empowering
life
sanofi
media
relations
contact
sally
bain
tel
sanofi
investor
relations
contacts
paris
eva
arnaud
delepine
yvonne
naughton
sanofi
investor
relations
contacts
north
america
felix
lauscher
fara
berkowitz
suzanne
greco
sanofi
ir
main
line
tel
ir
https
en
investors
contact
regeneron
media
relations
contact
sharon
chen
tel
regeneron
investor
relations
contact
vesna
tosic
tel
sanofi
statements
press
release
contains
statements
defined
private
securities
litigation
reform
act
amended
statements
statements
historical
facts
statements
include
projections
estimates
regarding
marketing
potential
product
regarding
potential
future
revenues
product
statements
generally
identified
words
expects
anticipates
believes
intends
estimates
plans
similar
expressions
although
sanofi
management
believes
expectations
reflected
statements
reasonable
investors
cautioned
information
statements
subject
various
risks
uncertainties
many
difficult
predict
generally
beyond
control
sanofi
could
cause
actual
results
developments
differ
materially
expressed
implied
projected
information
statements
risks
uncertainties
include
among
things
unexpected
regulatory
actions
delays
government
regulation
generally
could
affect
availability
commercial
potential
product
fact
product
may
commercially
successful
uncertainties
inherent
research
development
including
future
clinical
data
analysis
existing
clinical
data
relating
product
including
post
marketing
unexpected
safety
quality
manufacturing
issues
competition
general
risks
associated
intellectual
property
related
future
litigation
ultimate
outcome
litigation
volatile
economic
market
conditions
impact
us
customers
suppliers
vendors
business
partners
financial
condition
one
well
employees
global
economy
whole
material
effect
foregoing
could
also
adversely
impact
us
situation
changing
rapidly
additional
impacts
may
arise
currently
aware
may
exacerbate
previously
identified
risks
risks
uncertainties
also
include
uncertainties
discussed
identified
public
filings
sec
amf
made
sanofi
including
listed
risk
factors
cautionary
statement
regarding
statements
sanofi
annual
report
form
year
ended
december
required
applicable
law
sanofi
undertake
obligation
update
revise
information
statements
regeneron
statements
use
digital
media
press
release
includes
statements
involve
risks
uncertainties
relating
future
events
future
performance
regeneron
pharmaceuticals
regeneron
company
actual
events
results
may
differ
materially
statements
words
anticipate
expect
intend
plan
believe
seek
estimate
variations
words
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
concern
risks
uncertainties
include
among
others
impact
virus
caused
pandemic
regeneron
business
employees
collaborators
suppliers
third
parties
regeneron
relies
regeneron
collaborators
ability
continue
conduct
research
clinical
programs
regeneron
ability
manage
supply
chain
net
product
sales
products
marketed
regeneron
collaborators
collectively
regeneron
products
global
economy
nature
timing
possible
success
therapeutic
applications
regeneron
products
regeneron
product
candidates
research
clinical
programs
underway
planned
including
without
limitation
dupilumab
patients
years
older
eosinophilic
esophagitis
uncertainty
market
acceptance
commercial
success
regeneron
products
product
candidates
impact
studies
whether
conducted
regeneron
others
whether
mandated
voluntary
including
study
discussed
press
release
commercial
success
regeneron
products
dupixent
product
candidates
likelihood
timing
scope
possible
regulatory
approval
commercial
launch
regeneron
product
candidates
new
indications
regeneron
products
dupixent
treatment
eosinophilic
esophagitis
pediatric
asthma
pediatric
atopic
dermatitis
chronic
obstructive
pulmonary
disease
bullous
pemphigoid
prurigo
nodularis
chronic
spontaneous
urticaria
food
environmental
allergies
potential
indications
safety
issues
resulting
administration
regeneron
products
dupixent
product
candidates
patients
including
serious
complications
side
effects
connection
use
regeneron
products
product
candidates
clinical
trials
determinations
regulatory
administrative
governmental
authorities
may
delay
restrict
regeneron
ability
continue
develop
commercialize
regeneron
products
product
candidates
ongoing
regulatory
obligations
oversight
impacting
regeneron
products
research
clinical
programs
business
including
relating
patient
privacy
availability
extent
reimbursement
regeneron
products
payers
including
private
payer
healthcare
insurance
programs
health
maintenance
organizations
pharmacy
benefit
management
companies
government
programs
medicare
medicaid
coverage
reimbursement
determinations
payers
new
policies
procedures
adopted
payers
competing
drugs
product
candidates
may
superior
cost
effective
regeneron
products
product
candidates
extent
results
research
development
programs
conducted
regeneron
collaborators
may
replicated
studies
lead
advancement
product
candidates
clinical
trials
therapeutic
applications
regulatory
approval
ability
regeneron
manufacture
manage
supply
chains
multiple
products
product
candidates
ability
regeneron
collaborators
suppliers
third
parties
applicable
perform
manufacturing
filling
finishing
packaging
labeling
distribution
steps
related
regeneron
products
product
candidates
unanticipated
expenses
costs
developing
producing
selling
products
ability
regeneron
meet
financial
projections
guidance
changes
assumptions
underlying
projections
guidance
potential
license
collaboration
agreement
including
regeneron
agreements
sanofi
bayer
teva
pharmaceutical
industries
respective
affiliated
companies
applicable
cancelled
terminated
risks
associated
intellectual
property
parties
pending
future
litigation
relating
thereto
including
without
limitation
patent
litigation
related
proceedings
relating
aflibercept
injection
dupixent
alirocumab
litigation
proceedings
government
investigations
relating
company
operations
ultimate
outcome
proceedings
investigations
impact
foregoing
may
regeneron
business
prospects
operating
results
financial
condition
complete
description
material
risks
found
regeneron
filings
securities
exchange
commission
including
form
year
ended
december
form
quarterly
period
ended
june
statements
made
based
management
current
beliefs
judgment
reader
cautioned
rely
statements
made
regeneron
regeneron
undertake
obligation
update
publicly
statement
including
without
limitation
financial
projection
guidance
whether
result
new
information
future
events
otherwise
regeneron
uses
media
investor
relations
website
social
media
outlets
publish
important
information
company
including
information
may
deemed
material
investors
financial
information
regeneron
routinely
posted
accessible
regeneron
media
investor
relations
website
http
twitter
feed
http
regeneron
attachment
